Key Points
- CFO Ben Taylor sold 7,956 shares of Recursion (NASDAQ:RXRX) on March 17 at an average price of $3.39, trimming his position by 0.67% to 1,180,318 shares valued at about $4.0M.
- Recursion beat Q expectations with an EPS loss of $0.21 versus -$0.28 and revenue of $35.54M (up 671.7% YoY), but still posts a deeply negative net margin (-863%); the stock traded down 1.4% to $3.28 and has a $1.73B market cap.
- Major institutions like Vanguard, ARK and State Street materially increased stakes in Q4, leaving roughly 89.06% institutional ownership, while analysts hold a consensus Hold rating with an average target of $9.40.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CFO Ben Taylor sold 7,956 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the completion of the transaction, the chief financial officer owned 1,180,318 shares in the company, valued at $4,001,278.02. This trade represents a 0.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Recursion Pharmaceuticals Stock Down 1.4%
Recursion Pharmaceuticals stock traded down $0.05 during trading hours on Thursday, reaching $3.28. The stock had a trading volume of 3,215,125 shares, compared to its average volume of 19,260,268. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -2.22 and a beta of 0.97. The business's 50 day moving average price is $3.95 and its 200-day moving average price is $4.55. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.98 and a 52 week high of $7.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.50 and a quick ratio of 5.50.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The business had revenue of $35.54 million for the quarter, compared to analysts' expectations of $24.56 million. During the same period last year, the business earned ($0.53) EPS. The company's revenue was up 671.7% compared to the same quarter last year. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Recursion Pharmaceuticals by 18.6% in the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company's stock worth $192,998,000 after acquiring an additional 7,407,606 shares during the last quarter. ARK Investment Management LLC lifted its position in Recursion Pharmaceuticals by 11.2% during the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company's stock worth $152,626,000 after acquiring an additional 3,771,357 shares during the period. State Street Corp grew its stake in Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company's stock valued at $103,616,000 after purchasing an additional 7,064,963 shares during the last quarter. Geode Capital Management LLC grew its stake in Recursion Pharmaceuticals by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company's stock valued at $44,731,000 after purchasing an additional 1,310,695 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $23,473,000. 89.06% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on RXRX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 26th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Bank of America decreased their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "neutral" rating for the company in a research note on Wednesday, February 25th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Finally, Wall Street Zen raised shares of Recursion Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday, February 28th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $9.40.
View Our Latest Analysis on RXRX
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
